Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

RSS icon
cross market hospital mergers

Abiomed, Biosense Webster, Cerenovus now all known as Johnson & Johnson MedTech

These companies were already part of the Johnson & Johnson family, but they had still retained their previous brand names. Now, each one is officially going by Johnson & Johnson MedTech. 

Map of Congressional districts and the rate of amputations based on medicare data showing Mississippi delta region with the highest number of amputation procedures per year. Dr. Fakorede located his practice there to try and combat extremely the high PAD and CLI rates.

PAD is a public health crisis say cardiovascular societies

September is peripheral artery disease (PAD) awareness month, and medical societies are using it to promote awareness for patients and referring physicians to act against the debilitating disease.
 

Thumbnail

‘An excellent outcome’: TAVR safe and effective for patients in their nineties

Bleeding and vascular complications were more common, but one-year outcomes confirmed patients in their nineties should still be considered for TAVR.

Pausing oral anticoagulation during TAVR reduces bleeding risk

The findings, based on data from more than 800 TAVR patients, suggest that skipping OAC medications for a small amount of time could make a big impact.

OCT-guided PCI, or optical coherence tomography-guided percutaneous coronary intervention.

OCT-guided PCI boosts outcomes when treating complex lesions

When PCI patients present with complex lesions, optical coherence tomography may provide significant value.

Banner ASC in Sun City, Arizona.

PAD patients fare better when they have a strong support system

PAD patients with a strong social support system were associated with better outcomes in a new analysis published in the Journal of Vascular Surgery.

The U.S. Food and Drug Administration (FDA) has announced that Inari Medical is recalling its ClotTriever XL catheter for removing blood clots and other blockages from large blood vessels. The news comes after the FDA received several reports of “serious adverse events” due to the device becoming entrapped or blocking arteries in the patient’s lungs. Six deaths and four other patient injuries have been associated with the issue so far.

FDA announces recall of Inari Medical catheter after 6 deaths, 4 injuries

The FDA ruled that this is a Class I recall due to the significant risks for patients. Customers are not required to return the devices, however. Inari Medical has provided updated warnings and recommendations that should be followed. 

pharmaceutical drug approval process

Drugmaker to ‘challenge’ FDA after only receiving tentative approval for inhaled PAH treatment

An exclusivity agreement is stopping Liquidia Corporation from gaining full FDA approval of its new inhalation powder for pulmonary arterial hypertension. The company said it is disappointed with the agency's decision and plans to "take quick action."

Displaying 25 - 32 of 798
Design by Adaptive Theme